Page last updated: 2024-11-13
gpi0100
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
GPI0100: quillaja saponin semi-synthetic analog; a systemic and mucosal adjuvant, has potential use in the development of vaccines against periodontal, as well as other pathogens [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Quillaja | genus | A plant genus of the family ROSACEAE whose members produce SAPONINS.[MeSH] | Quillajaceae | [no description available] |
Cross-References
ID Source | ID |
---|---|
PubMed CID | 56841660 |
MeSH ID | M0465770 |
Synonyms (6)
Synonym |
---|
gpi 0100 |
gpi0100 |
ic5v8479h3 , |
gpi-0100 |
328056-98-0 |
unii-ic5v8479h3 |
Research Excerpts
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
"This is the first phase I, open-label study to assess the safety, pharmacokinetics, and antitumor activity of a novel immunotherapeutic regimen known as Folate Immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17, a folate-targeted hapten immunotherapy that targets folate receptor expressing cancer cells), which is designed to convert poorly immunogenic tumors to highly immunogenic tumors in patients with metastatic renal cell carcinoma." | ( A phase I study of folate immune therapy (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) in patients with renal cell carcinoma. Amato, RJ; Ellis, R; Low, PS; Lu, Y; Shetty, A, 2013) | 0.39 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (16)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (37.50) | 29.6817 |
2010's | 9 (56.25) | 24.3611 |
2020's | 1 (6.25) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 11.77
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.77) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (6.25%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 15 (93.75%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |